VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year ...

UBS recently reaffirmed its Buy rating on Veracyte after the company’s fourth-quarter testing revenue came in ahead of ...

Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, ...

(Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor ...

A downtrend has been apparent in Veracyte (VCYT) lately with too much selling pressure. The stock has declined 20% over the ...

Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry’s 3.9% rise and the S&P 500 composite’s 24.4% gain. With a ...

Veracyte VCYT has consistently gained from the strength of its Afirma and Decipher tests. With Decipher expanding into metastatic and localized disease areas, the growth is likely to continue in the ...

The price trend for Veracyte (VCYT) has been bearish lately and the stock has lost 11.6% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

With its range of products, Veracyte displays a robust and diverse portfolio, targeting multiple areas in oncology. Veracyte's recent data underscores the company's innovative edge in the field of ...

Veracyte's Q3 2023 performance shows a robust 19% YOY revenue growth, driven by an increase in testing revenue and test volume. Financial health is strong with a high current ratio, positive ...

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays ...